Kazuyuki Gyoten

Dr. Kazuyuki Gyoten


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 July 2022 in Surgical Endoscopy
Verified
Journal Article
Closed access
PDF file
ATAkihiro Tanemura
Akihiro Tanemura
SMShugo Mizuno
Shugo Mizuno
KMKoki Maeda
Koki Maeda
TSToru Shinkai
Toru Shinkai
TITakahiro Ito
Takahiro Ito
HSHiroyuki Sakurai
Hiroyuki Sakurai

18 July 2025 in Surgical Oncology
Verified
Journal Article
Open access
AHAoi Hayasaki
Aoi Hayasaki
SMShugo Mizuno
Shugo Mizuno
BKBenson Kaluba
Benson Kaluba
YSYuki Segi
Yuki Segi
HKHaruna Komatsubara
Haruna Komatsubara
MKMasashi Kishiwada
Masashi Kishiwada
In this study, we present our institution's treatment outcomes and surgical strategies for patients with localized pancreatic ductal adenocarcinoma (PDAC). The study retrospectively reviewed clinical data of 397 patients with localized PDAC who were enrolled in a gemcitabine and S-1 based chemoradiotherapy (GS-CRT) protocol between September 2011 and March 2023. Following GS-CRT, pancreatectomy was performed and concomitant vascular resection with subsequent reconstruction was done, if required, in order to achieve R0 resection margins. From the 397 patients, 366 (92.2 %) completed the GS-CRT. A total of 359 patients were adequately re-evaluated after GS-CRT and categorized as having resectable (R; n = 77), borderline resectable with superior mesenteric vein/portal vein involvement (BR-PV; n = 40), borderline resectable with arterial involvement (BR-A; n = 94), or unresectable locally advanced (UR-LA; n = 148) tumors, respectively. From these, 202 patients with R (n = 63), BR-PV (n = 31), BR-A (n = 56) and UR-LA (n = 52) PDAC underwent curative-intent pancreatectomy. The R0 resection rates and median survival times for disease-specific survival (DSS) according to resectability were favorable: 98.4 %, 93.5 %, 92.9 %, and 80.8 %, and 62.7, 66.1, 41.8, and 36.2 months, respectively. Prognostic factors for DSS among the 202 resected patients included performance status, pre-operative carbohydrate antigen 19-9 and carcinoembryonic antigen serum levels, pre-operative tumor resectability, pathological T factor and receipt of adjuvant chemotherapy. In the resected UR-LA patients, adjuvant chemotherapy was a significant prognostic factor of survival outcomes. GS-CRT followed by pancreatectomy is feasible and a beneficial treatment strategy for PDAC. Therefore, a safe and reliable surgical approach that ensures R0 resection margins and enables subsequent adjuvant chemotherapy is essential.

16 May 2025 in Medicine
Verified
Journal Article
Open access
YMYasuhiro Murata
Yasuhiro Murata
SMShugo Mizuno
Shugo Mizuno
MKMasashi Kishiwada
Masashi Kishiwada
AHAoi Hayasaki
Aoi Hayasaki
MNMotonori Nagata
Motonori Nagata
NKNaohisa Kuriyama
Naohisa Kuriyama
The efficacy of preoperative chemoradiotherapy (CRT) for anatomically resectable pancreatic adenocarcinoma (R-PDAC) remains contentious. This study aims to elucidate the treatment outcomes of preoperative CRT for R-PDAC and to identify prognostic factors. This retrospective study included 109 R-PDAC patients treated with gemcitabine- or S-1 plus gemcitabine-based preoperative CRT from February 2005 to April 2023. Cox proportional hazards regression was employed to identify factors associated with worse overall survival (OS). Among the 109 cases, 90 patients (82.6%) underwent curative-intent resection following CRT. The median OS for the entire cohort was 36.5 months, significantly longer in resected cases than in unresected cases (40.6 vs 11.4 months). Multivariate analysis identified pretreatment serum levels of carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA19-9) and the Eastern Cooperative Oncology Group performance status ≥1 as independent prognostic factors. When these factors were scored (risk score 0–3) using pre-CRT serum CA19-9 level (≥640 U/mL) and CEA (≥6.1 ng/mL), OS for risk scores 1 (n = 41), 2 (n = 20) or 3 (n = 6) was significantly shorter than for risk score 0 (n = 42) (score 0 vs 1 vs 2 vs 3: 49.1 vs 33.8 vs 16.1 vs 16.8 months). The presence of portal vein invasion on imaging and post-CRT serum CA 19-9 level (≥111 U/mL) were independent prognostic factors in resected cases. Biological factors, including serum levels of CA19-9 and CEA, along with conditional factor of Eastern Cooperative Oncology Group performance status ≥1, were identified as independent prognostic factors for R-PDAC patients treated with preoperative CRT. Preoperative CRT is considered effective for cases lacking these risk factors.


8 October 2026 in Cancers
Verified
Journal Article
Open access
PDF file
NKNaohisa Kuriyama
Naohisa Kuriyama
SMShugo Mizuno
Shugo Mizuno
YSYuki Segi
Yuki Segi
HKHaruna Komatsubara
Haruna Komatsubara
KGKazuyuki Gyoten
Kazuyuki Gyoten
MKMasashi Kishiwada
Masashi Kishiwada
Objectives: The long-term impact of neoadjuvant chemotherapy (NAC) based on anatomical resectability for perihilar cholangiocarcinoma (PHC) remains unclear. We evaluated the mature long-term outcomes of our multidisciplinary treatment strategy based on anatomical resectability classification and regional lymph node (LN) status using gemcitabine plus S-1 (NAC-GS). Methods: Between September 2010 and August 2021, 110 consecutive PHC patients were classified as resectable (R; n = 47), borderline resectable (BR; n = 38), or unresectable locally advanced (UR-LA; n = 25) according to our anatomical resectability classification. NAC-GS was administered to patients with clinically positive LN metastasis and to BR and UR-LA patients. Long-term overall survival (OS), recurrence-free survival (RFS), and prognostic factors were evaluated. Results: NAC-GS was administered to 72 patients (65.5%). Curative-intent resection was achieved in 40 (85.1%), 25 (65.8%), and 6 (24.0%) patients in the R, BR, and UR-LA groups, respectively. In the overall cohort, anatomical resectability significantly stratified OS (p = 0.032). However, among patients who underwent curative-intent resection, OS and RFS were comparable across the three resectability groups. Those receiving NAC-GS showed favorable long-term survival despite having more advanced disease characteristics; however, this comparison was limited to selected patients who ultimately proceeded to surgery. Multivariable analysis identified preoperative serum carcinoembryonic antigen ≥5.5 ng/mL (HR: 3.174, p = 0.003), non-adjuvant therapy (HR: 2.222, p = 0.023) and pathological T4 (HR: 2.397, p = 0.037) as independent predictors of poor survival. Conclusions: Anatomical resectability was associated with long-term prognosis and the likelihood of achieving curative-intent resection. Selected patients who ultimately underwent curative-intent resection after NAC-GS showed favorable long-term outcomes; however, these findings do not establish a survival benefit of NAC-GS over upfront surgery. Prospective multi-institutional validation is warranted.

2 November 2026 in Cancers
Verified
Journal Article
Open access
PDF file
HKHaruna Komatsubara
Haruna Komatsubara
SMShugo Mizuno
Shugo Mizuno
DNDaisuke Noguchi
Daisuke Noguchi
NKNaohisa Kuriyama
Naohisa Kuriyama
AHAoi Hayasaki
Aoi Hayasaki
MKMasashi Kishiwada
Masashi Kishiwada
Background/Objectives: Oncological outcomes in borderline resectable pancreatic ductal adenocarcinoma (BR-PDAC) remain unclear. This long-term observational study evaluated these outcomes in patients with BR-PDAC treated with a consistent neoadjuvant chemoradiotherapy (CRT) regimen and explored host-related prognostic markers. Methods: We retrospectively analyzed 206 patients with PDAC who received neoadjuvant gemcitabine plus S-1 with concurrent radiotherapy between 2011 and 2022. Biological BR was defined as anatomically resectable disease with an initial carbohydrate antigen 19-9 (CA19-9) level ≥500 U/mL. Anatomical BR was subdivided into portal venous involvement (BR-PV) and arterial involvement (BR-A). Outcomes were compared according to resectability and surgical resection, with resectable (R) patients as a reference. Prognostic factors among resected BR patients were assessed using multivariable Cox regression analysis. Results: The median follow-up was 62.5 months. Resection rates were 85.7%, 83.3%, 69.8%, and 55.6% for R, biological BR, BR-PV, and BR-A, respectively. Although the resection rate of biological BR was similar to that of R, its survival did not differ significantly from that of anatomical BR. Across all BR subtypes, surgical resection was associated with longer overall survival. Among resected patients, the post-CRT neutrophil-lymphocyte-to-monocyte ratio (NL/M), a peripheral blood cell index, was associated with overall survival (hazard ratio 1.020, p = 0.009). Patients with a high post-CRT NL/M had poorer prognosis than those with a low NL/M (p = 0.001). Conclusions: Biological and anatomical BR-PDAC showed no significant difference in long-term survival after neoadjuvant CRT, and surgical resection was associated with longer survival across BR subtypes. Post-CRT NL/M was associated with overall survival after resection and may serve as a potential host-related prognostic marker, although further validation is needed.